Moody's Ratings ("Moody's) affirmed Baxter International Inc.'s ("Baxter") ratings, including its Baa2 senior unsecured ratings and Prime-2 commercial paper rating. The outlook remains stable. The ratings affirmation follows the company's announcement that it plans to sell its Kidney Care business...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Moody's Investors Service (Moody's) commented that the announcement by Baxter International Inc. ("Baxter") that it reached an agreement to divest its BioPharma Solutions ("BPS") business will help in deleveraging and strengthen the company's credit metrics. Baxter (Baa2, stable) will receive $4.25 ...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Moody's Investors Service ("Moody's") affirmed Baxter International Inc's ("Baxter") ratings, including its Baa2 senior unsecured rating and Prime-2 commercial paper rating. The outlook remains stable. The ratings affirmation follows the company's announcement that it plans to spin off its Renal...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.